flurbiprofen has been researched along with Sore Throat in 24 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
Excerpt | Relevance | Reference |
---|---|---|
"According to the results of the study, the use of a drug based on a combination of flurbiprofen and cetylpyridinium chloride was accompanied by a rapid and pronounced decrease in sore throat and pharyngeal hyperemia in patients with upper respiratory tract infections." | 9.51 | [Results of a clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat]. ( Galustyan, AN; Gonik, MI; Sedavnykh, IS, 2022) |
"To evaluate the efficacy and safety of a combined topical drug with flurbiprofen and cetylpyridinium chloride compared with a monocomponent drug in patients with sore throat associated with manifestations of acute pharyngitis, tonsillitis or with exacerbation of chronic forms of pharyngitis or tonsillitis." | 9.51 | [Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat]. ( Galustyan, AN; Poromov, AA; Sedavnykh, IS, 2022) |
"Both oral flurbiprofen and benzydamine hydrochloride sprays were found to be more effective than placebo in decreasing the incidence and severity of postoperative sore throat and hoarseness, with no adverse effects." | 9.30 | Oral flurbiprofen spray for postoperative sore throat and hoarseness: a prospective, randomized, double-blind, placebo-controlled study. ( Gul, F; Muderris, T; Sancak, M; Tezcan, G; Ugur, G, 2019) |
"Flurbiprofen spray provides rapid, long-lasting and clinically meaningful relief from sore throat (ANZCTR: ACTRN12612000457842)." | 9.27 | Meaningful relief with flurbiprofen 8.75 mg spray in patients with sore throat due to upper respiratory tract infection. ( Bloch, M; de Looze, F; DeVito, R; Montgomery, B; Russo, M; Shephard, A, 2018) |
" Adults with sore throat due to upper respiratory tract infection (onset ≤ four days) took one dose of flurbiprofen (n = 249) or placebo spray (n = 256); after six hours, they could re-dose every three-six hours as required, for three days (max." | 9.22 | Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trial. ( Aspley, S; Bloch, M; de Looze, F; Montgomery, B; Russo, M; Shephard, A; Smith, G, 2016) |
"Over the first 24 h, patients treated with flurbiprofen lozenges reported significantly greater reductions in sore throat pain (47%) as well as difficulty swallowing (66%) and swollen throat (40%) compared with placebo (all p < 0." | 9.22 | Flurbiprofen 8.75 mg lozenges for treating sore throat symptoms: a randomized, double-blind, placebo-controlled study. ( Aspley, S; Rezuke, J; Sanner, K; Savino, L; Schachtel, BP; Schachtel, E; Shea, T; Shephard, A, 2016) |
"Dezocine has notable analgesia effect for postoperative sore throat, so it is a better choice to carry out postoperative analgesia after maxillofacial procedures." | 9.19 | [Effects of dezocine on postoperative sore throat after maxillofacial procedures: a comparison with flurbiprofen axetil]. ( Jiao, L; Liu, RC, 2014) |
"Adults (n=198) with moderate or severe acute sore throat and findings of pharyngitis on a Tonsillo-Pharyngitis Assessment (TPA) were randomly assigned to use either flurbiprofen 8." | 9.19 | Utility of the sore throat pain model in a multiple-dose assessment of the acute analgesic flurbiprofen: a randomized controlled study. ( Aspley, S; Schachtel, B; Schachtel, E; Shea, T; Shephard, A; Smith, G, 2014) |
"Participants with sore throat of onset within the past 4 days received either flurbiprofen 8." | 9.17 | Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial. ( Bloch, M; de Looze, F; Morris, C; Russo, M; Shephard, A, 2013) |
"To compare efficacy and safety of strepfen (flurbiprofen) to those of oral paracetamol in acute infections of the upper respiratory tracts for relief of throat pain (TP)." | 9.11 | [Results of an open prospective controlled randomized comparative trial of flurbiprofen and paracetamol efficacy and tolerance in patients with throat pain]. ( Balandin, AV; Dimova, AD; Sedinkin, AA, 2005) |
"In this double-blind study, 301 patients with subjective and objective signs of sore throat were randomly assigned to flurbiprofen 8." | 9.09 | Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: a randomised, double-blind, placebo-controlled study of efficacy and safety. ( Charlesworth, A; Christian, J; Miller, K; Nimmo, WS; Speight, J; Watson, N, 2000) |
"Sore throat is often over-treated with antibiotics, therefore there is a need for non-antibiotic treatments that provide effective relief." | 6.82 | Efficacy of flurbiprofen 8.75 mg lozenge in patients with a swollen and inflamed sore throat. ( Aspley, S; Sanner, K; Savino, L; Schachtel, B; Schachtel, E; Shephard, A, 2016) |
"The current study reflected the treatment of sore throat in general practice, investigating multiple dose efficacy where patients also had access to concomitant antibiotics and rescue medication." | 6.70 | Multidose flurbiprofen 8.75 mg lozenges in the treatment of sore throat: a randomised, double-blind, placebo-controlled study in UK general practice centres. ( Blagden, M; Charlesworth, A; Christian, J; Miller, K, 2002) |
"Flurbiprofen, 5." | 6.70 | Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model. ( Christian, J; Gibb, IA; Homan, HD; Schachtel, BP, 2002) |
"According to the results of the study, the use of a drug based on a combination of flurbiprofen and cetylpyridinium chloride was accompanied by a rapid and pronounced decrease in sore throat and pharyngeal hyperemia in patients with upper respiratory tract infections." | 5.51 | [Results of a clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat]. ( Galustyan, AN; Gonik, MI; Sedavnykh, IS, 2022) |
"To evaluate the efficacy and safety of a combined topical drug with flurbiprofen and cetylpyridinium chloride compared with a monocomponent drug in patients with sore throat associated with manifestations of acute pharyngitis, tonsillitis or with exacerbation of chronic forms of pharyngitis or tonsillitis." | 5.51 | [Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat]. ( Galustyan, AN; Poromov, AA; Sedavnykh, IS, 2022) |
"Both oral flurbiprofen and benzydamine hydrochloride sprays were found to be more effective than placebo in decreasing the incidence and severity of postoperative sore throat and hoarseness, with no adverse effects." | 5.30 | Oral flurbiprofen spray for postoperative sore throat and hoarseness: a prospective, randomized, double-blind, placebo-controlled study. ( Gul, F; Muderris, T; Sancak, M; Tezcan, G; Ugur, G, 2019) |
"Flurbiprofen spray provides rapid, long-lasting and clinically meaningful relief from sore throat (ANZCTR: ACTRN12612000457842)." | 5.27 | Meaningful relief with flurbiprofen 8.75 mg spray in patients with sore throat due to upper respiratory tract infection. ( Bloch, M; de Looze, F; DeVito, R; Montgomery, B; Russo, M; Shephard, A, 2018) |
" Adults with sore throat due to upper respiratory tract infection (onset ≤ four days) took one dose of flurbiprofen (n = 249) or placebo spray (n = 256); after six hours, they could re-dose every three-six hours as required, for three days (max." | 5.22 | Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trial. ( Aspley, S; Bloch, M; de Looze, F; Montgomery, B; Russo, M; Shephard, A; Smith, G, 2016) |
"Over the first 24 h, patients treated with flurbiprofen lozenges reported significantly greater reductions in sore throat pain (47%) as well as difficulty swallowing (66%) and swollen throat (40%) compared with placebo (all p < 0." | 5.22 | Flurbiprofen 8.75 mg lozenges for treating sore throat symptoms: a randomized, double-blind, placebo-controlled study. ( Aspley, S; Rezuke, J; Sanner, K; Savino, L; Schachtel, BP; Schachtel, E; Shea, T; Shephard, A, 2016) |
"Dezocine has notable analgesia effect for postoperative sore throat, so it is a better choice to carry out postoperative analgesia after maxillofacial procedures." | 5.19 | [Effects of dezocine on postoperative sore throat after maxillofacial procedures: a comparison with flurbiprofen axetil]. ( Jiao, L; Liu, RC, 2014) |
"Adults (n=198) with moderate or severe acute sore throat and findings of pharyngitis on a Tonsillo-Pharyngitis Assessment (TPA) were randomly assigned to use either flurbiprofen 8." | 5.19 | Utility of the sore throat pain model in a multiple-dose assessment of the acute analgesic flurbiprofen: a randomized controlled study. ( Aspley, S; Schachtel, B; Schachtel, E; Shea, T; Shephard, A; Smith, G, 2014) |
"Participants with sore throat of onset within the past 4 days received either flurbiprofen 8." | 5.17 | Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial. ( Bloch, M; de Looze, F; Morris, C; Russo, M; Shephard, A, 2013) |
"To compare efficacy and safety of strepfen (flurbiprofen) to those of oral paracetamol in acute infections of the upper respiratory tracts for relief of throat pain (TP)." | 5.11 | [Results of an open prospective controlled randomized comparative trial of flurbiprofen and paracetamol efficacy and tolerance in patients with throat pain]. ( Balandin, AV; Dimova, AD; Sedinkin, AA, 2005) |
"In this double-blind study, 301 patients with subjective and objective signs of sore throat were randomly assigned to flurbiprofen 8." | 5.09 | Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: a randomised, double-blind, placebo-controlled study of efficacy and safety. ( Charlesworth, A; Christian, J; Miller, K; Nimmo, WS; Speight, J; Watson, N, 2000) |
"In practice, flurbiprofen lozenges have a negative risk-benefit balance in the treatment of sore throat; it is better to suck real sweets and, if necessary, take oral paracetamol." | 3.74 | Flurbiprofen: new indication. Lozenges: NSAIDs are not to be taken like sweets! ( , 2007) |
"Sore throat is often over-treated with antibiotics, therefore there is a need for non-antibiotic treatments that provide effective relief." | 2.82 | Efficacy of flurbiprofen 8.75 mg lozenge in patients with a swollen and inflamed sore throat. ( Aspley, S; Sanner, K; Savino, L; Schachtel, B; Schachtel, E; Shephard, A, 2016) |
"The current study reflected the treatment of sore throat in general practice, investigating multiple dose efficacy where patients also had access to concomitant antibiotics and rescue medication." | 2.70 | Multidose flurbiprofen 8.75 mg lozenges in the treatment of sore throat: a randomised, double-blind, placebo-controlled study in UK general practice centres. ( Blagden, M; Charlesworth, A; Christian, J; Miller, K, 2002) |
"Flurbiprofen, 5." | 2.70 | Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model. ( Christian, J; Gibb, IA; Homan, HD; Schachtel, BP, 2002) |
"Lozenges are commonly applied in the treatment of sore throat." | 1.48 | Predicting local drug availability of locally acting lozenges: From method design to a linear level A IVIVC. ( Gutknecht, SI; Klein, S; Tietz, K, 2018) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (4.17) | 18.7374 |
1990's | 1 (4.17) | 18.2507 |
2000's | 5 (20.83) | 29.6817 |
2010's | 15 (62.50) | 24.3611 |
2020's | 2 (8.33) | 2.80 |
Authors | Studies |
---|---|
Galustyan, AN | 4 |
Sedavnykh, IS | 4 |
Gonik, MI | 1 |
Poromov, AA | 3 |
de Looze, F | 3 |
Russo, M | 3 |
Bloch, M | 3 |
Montgomery, B | 2 |
Shephard, A | 9 |
DeVito, R | 1 |
Schachtel, B | 4 |
Schachtel, E | 5 |
Lorton, MB | 1 |
Shea, T | 4 |
Aspley, S | 7 |
Muderris, T | 1 |
Tezcan, G | 1 |
Sancak, M | 1 |
Gul, F | 1 |
Ugur, G | 1 |
Tietz, K | 1 |
Gutknecht, SI | 1 |
Klein, S | 1 |
Morris, C | 1 |
Calapai, G | 1 |
Imbesi, S | 1 |
Cafeo, V | 1 |
Ventura Spagnolo, E | 1 |
Minciullo, PL | 1 |
Caputi, AP | 1 |
Gangemi, S | 1 |
Milone, L | 1 |
Smith, G | 4 |
Sanner, K | 3 |
Savino, L | 3 |
Rezuke, J | 2 |
Aydın, GB | 1 |
Ergil, J | 1 |
Polat, R | 1 |
Sayın, M | 1 |
Akelma, FK | 1 |
Jiao, L | 1 |
Liu, RC | 1 |
Li, RP | 1 |
Xue, FS | 1 |
Cui, XL | 1 |
Schachtel, BP | 3 |
Sedinkin, AA | 1 |
Balandin, AV | 1 |
Dimova, AD | 1 |
Romano, A | 1 |
Pietrantonio, F | 1 |
Watson, N | 1 |
Nimmo, WS | 1 |
Christian, J | 3 |
Charlesworth, A | 2 |
Speight, J | 1 |
Miller, K | 2 |
Blagden, M | 1 |
Homan, HD | 1 |
Gibb, IA | 1 |
Hahn, R | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Onset-of-Action Study Utilizing the Double-Stopwatch Method[NCT01986361] | Phase 3 | 122 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
Effect of Over-the-counter Non-steroidal Anti-inflammatory Treatments on Cough Reflex Sensitivity in Subjects With Upper Respiratory Tract Infection[NCT05955885] | Early Phase 1 | 120 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
Alleviation of Upper Respiratory Inflammation and Associated Common Cold Symptoms[NCT06106880] | Phase 1 | 157 participants (Actual) | Interventional | 2022-05-25 | Completed | ||
A Repeat-Dose, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Study to Determine the Safety and Efficacy of Flurbiprofen 8.75 mg Lozenge Compared to Its Vehicle Control Lozenge in Patients With Painful Pharyngitis[NCT01048866] | Phase 3 | 198 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
A Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study to Determine the Efficacy, Onset, and Duration of Action of Flurbiprofen 8.75 mg Lozenge Compared to Its Vehicle Control Lozenge in Patients With Painful Pharyngitis[NCT01049334] | Phase 3 | 204 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Time to first indication of sore throat relief, defined as any reduction or decrease in STS observed during the 3 hours post dose. Participants who did not have any reduction in STS from baseline within 3 hours were censored to 3 hours.~The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: Circle the number that shows how sore your throat is now when you swallow. The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours." (NCT01986361)
Timeframe: up to 3 hours post dose on Day 1
Intervention | minutes (Median) |
---|---|
Flurbiprofen 8.75 mg Lozenge | 15.000 |
Placebo Lozenge | 20.000 |
"Time to pain reduction on the STS (defined as any reduction or decrease observed during the 3 hours post dose) for participants whose improvement was confirmed by a >=20% reduction in pain on the STPIS.~STS: The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: Circle the number that shows how sore your throat is now when you swallow. The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours.~STPIS: The participant was instructed to swallow and: Place a line on the Sore Throat Scale that best characterizes the severity of your sore throat now: 0mm=no pain and 100mm=severe pain. The STPIS was obtained at baseline, after the participant depressed the second stopwatch, and at 1, 2, and 3 hours postdose." (NCT01986361)
Timeframe: Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1
Intervention | minutes (Median) |
---|---|
Flurbiprofen 8.75 mg Lozenge | 15.000 |
Placebo Lozenge | NA |
"Time to first perceived pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the first stop watch when they experience any pain relief, termed perceived pain relief. Instructions to participants are: Stop the first stopwatch when you first feel any sore throat pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief of the throat pain you have now. Participants who did not have perceived pain relief were censored at 3 hours." (NCT01986361)
Timeframe: up to 3 hours post dose on Day 1
Intervention | minutes (Median) |
---|---|
Flurbiprofen 8.75 mg Lozenge | 10.867 |
Placebo Lozenge | 19.317 |
Time to first perceived pain relief on the first stopwatch that was confirmed by meaningful pain relief on the second stopwatch. Participants who had no meaningful pain relief within 3 hours from baseline were censored to 3 hours. (NCT01986361)
Timeframe: up to 3 hours post dose on Day 1
Intervention | minutes (Median) |
---|---|
Flurbiprofen 8.75 mg Lozenge | 13.200 |
Placebo Lozenge | NA |
"Time to meaningful pain relief is a patient-reported outcome (PRO) captured as part of the double stopwatch method. Participants depress the second stop watch when they experience what they perceive as meaningful pain relief. Instructions to participants are: Stop the second stopwatch when the sore throat pain relief is meaningful to you. This does not mean you feel completely better, although you might, but when you feel relief of throat pain that is meaningful to you. Participants who did not have perceived pain relief were censored at 3 hours." (NCT01986361)
Timeframe: up to 3 hours post dose on Day 1
Intervention | minutes (Median) |
---|---|
Flurbiprofen 8.75 mg Lozenge | 42.917 |
Placebo Lozenge | NA |
Defined as the percentage of participants who pressed the second stopwatch during the 3 hour evaluation period. (NCT01986361)
Timeframe: up to 3 hours post dose on Day 1
Intervention | percentage of participants (Number) |
---|---|
Flurbiprofen 8.75 mg Lozenge | 78.2 |
Placebo Lozenge | 47.6 |
Defined as the percentage of participants who pressed the first stopwatch during the 3 hour evaluation period. (NCT01986361)
Timeframe: up to 3 hours post dose on Day 1
Intervention | percentage of participants (Number) |
---|---|
Flurbiprofen 8.75 mg Lozenge | 97.0 |
Placebo Lozenge | 76.2 |
"The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: Circle the number that shows how sore your throat is now when you swallow. STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours, for a total of 24 post-dose measurements.~The time-weighted SPID combines relief magnitude (PID = change from baseline) as weighted by duration interval between ratings. SPID3 refers to measurements taken up to 3 hours post-baseline, and has a full range of -1332 (complete pain relief within 5 minutes of dosing that lasts for 3 hours) to 468 (drug escalates level of pain to a score of 10 and the pain stays at that level for 3 hours) using the mean baseline STS value 7.4 for this study." (NCT01986361)
Timeframe: Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -403.9 |
Placebo Lozenge | -166.4 |
"The participant was asked to evaluate his/her sore throat when swallowing using a vertical 0-10 Likert scale, where 0=not sore and 10=very sore. The participant was instructed: Circle the number that shows how sore your throat is now when you swallow. The STS was obtained at baseline, every 5 minutes after treatment during the first hour and every 10 minutes during the second and third hours." (NCT01986361)
Timeframe: Baseline (Day 1, pre-dose), up to 3 hours post dose on Day 1
Intervention | units on a scale (Mean) | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Minute 5 | Minute 10 | Minute 15 | Minute 20 | Minute 25 | Minute 30 | Minute 35 | Minute 40 | Minute 45 | Minute 50 | Minute 55 | Minute 60 | Minute 70 | Minute 80 | Minute 90 | Minute 100 | Minute 110 | Minute 120 | Minute 130 | Minute 140 | Minute 150 | Minute 160 | Minute 170 | Minute 180 | |
Flurbiprofen 8.75 mg Lozenge | -0.4 | -0.7 | -0.9 | -1.0 | -1.3 | -1.6 | -1.8 | -2.0 | -2.2 | -2.3 | -2.4 | -2.5 | -2.6 | -2.7 | -2.7 | -2.7 | -2.7 | -2.7 | -2.6 | -2.6 | -2.5 | -2.4 | -2.3 | -2.3 |
Placebo Lozenge | -0.4 | -0.6 | -0.6 | -0.6 | -0.7 | -1.0 | -1.0 | -1.1 | -1.2 | -1.3 | -1.1 | -1.1 | -1.2 | -1.1 | -1.0 | -1.0 | -1.0 | -1.0 | -1.0 | -0.9 | -0.8 | -0.9 | -0.8 | -0.8 |
(NCT01048866)
Timeframe: baseline (pre-dose), 2 hours post-dose
Intervention | degrees Fahrenheit (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -0.2 |
Placebo Lozenge | -0.0 |
(NCT01048866)
Timeframe: baseline (pre-dose), up to Day 7
Intervention | degrees Fahrenheit (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -0.4 |
Placebo Lozenge | -0.3 |
"The time weighted summed differences over 2 hours after taking a lozenge for all lozenges taken after the initial 24-hours post-baseline.~To measure the functional effect on pharyngitis, the participant was asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale prior to dosing, and 1 hour and 2 hours post dose. The participant was instructed to swallow and Place a line on the scale that best characterizes how difficult it is to swallow now. A mark at 0-mm indicated not difficult and 100-mm indicated very difficult. Data for multiple doses/days were averaged to obtain the values used for calculating DSS2. The full range for differences was -5626 to 6374 with negative values indicating improvement in pain intensity.~Assessments were summarized using a repeated measures mixed model, with treatment and center as a fixed effect, time since Baseline as a covariate, and a random effect for participants." (NCT01048866)
Timeframe: Days 2-7
Intervention | units on a scale (Least Squares Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -21.0 |
Placebo Lozenge | -15.5 |
"The time weighted summed differences over 2 hours after taking a lozenge for all lozenges taken after the initial 24-hours post-baseline.~The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale prior to dosing, and 1 hour and 2 hours post dose.~The patient was instructed to swallow and Place a line on the scale that best characterizes how swollen your throat feels now. A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. Data for multiple doses/days were averaged to obtain the values used for calculating SWoTS2. The full range for differences was -5396 to 6604 with negative values indicating improvement in pain intensity.~Assessments were summarized using a repeated measures mixed model, with treatment and center as a fixed effect, time since Baseline as a covariate, and a random effect for participants." (NCT01048866)
Timeframe: Days 2-7
Intervention | units on a scale (Least Squares Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -19.5 |
Placebo Lozenge | -13.4 |
"The time weighted summed differences over 2 hours after taking a lozenge after the initial 24-hours post-baseline.~STPIS is a validated 100-mm visual analog scale completed by participants that measures pain on swallowing (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from a measurement taken prior to taking a lozenge and at hours 1 + 2 after taking the lozenge during Days 2-7. Data for multiple doses/days were averaged to obtain the values used for calculating SPID2. The full range for SPID2 was -5843 to 6157 with negative values indicating improvement in pain intensity. Assessments were summarized using a repeated measures mixed model, with treatment and center as a fixed effect, time since Baseline as a covariate, and a random effect for participants." (NCT01048866)
Timeframe: Days 2-7
Intervention | units on a scale (Least Squares Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -22.7 |
Placebo Lozenge | -16.8 |
"STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9492 (complete pain relief within one hour of dosing that lasts 2 hours) to 2508 (maximum pain within 1 hour lasting 2 hours) using the mean baseline STPIS.~If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose." (NCT01048866)
Timeframe: baseline (pre-dose), post-dose: 1 hour, 2 hours
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -37.1 |
Placebo Lozenge | -17.9 |
"STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. The full range was -104412 (complete pain relief within 1 hour of dosing that lasts 24 hours) to 27588 (maximum pain within 1 hour lasting 24 hours) using the mean baseline STPIS.~Participants with a last recorded time point <21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose." (NCT01048866)
Timeframe: baseline (pre-dose), post-dose - hourly up to 24 hours
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -522.9 |
Placebo Lozenge | -326.5 |
"STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -115695 (no pain at any post-dose time (0) - average baseline) to 28505 (maximum possible pain (100) - average baseline).~Participants with their last recorded time point <21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imput" (NCT01048866)
Timeframe: baseline (pre-dose), 24 hours post dose (measured each hour post dose)
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -476.9 |
Placebo Lozenge | -351.3 |
"DSS measures difficulty swallowing (dysphagia) using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and Place a line on the scale that best characterizes how difficult it is to swallow now. A mark at 0-mm indicated not difficult and 100-mm indicated very difficult.~Data are reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9360 (no difficulty swallowing within 1 hour of dosing that lasts 2 hours) to 2640 (maximum difficulty swallowing within 1 hour of dosing lasting 2 hours) using the baseline DSS value.~Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation." (NCT01048866)
Timeframe: Baseline (pre-dose), Hours 1 and 2 post-dose
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -37.1 |
Placebo Lozenge | -18.1 |
"DSS measures difficulty swallowing (dysphagia) using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and Place a line on the scale that best characterizes how difficult it is to swallow now. A mark at 0-mm indicated not difficult and 100-mm indicated very difficult.~Data are reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -102960 (no difficulty swallowing within 1 hour of dosing that lasts 24 hours) to 29040 (maximum difficulty swallowing within 1 hour of dosing lasting 24 hours) using the baseline DSS value. Negative values indicate improvement in difficulty swallowing.~Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation." (NCT01048866)
Timeframe: Baseline (pre-dose), hourly readings to 24 hours post-dose
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -555.5 |
Placebo Lozenge | -379.4 |
"SwoTS measures how swollen a participant's throat felt using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and Place a line on the scale that best characterizes how swollen your throat feels now. A mark at 0-mm indicated not swollen and 100-mm indicated very swollen.~The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9120 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2880 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS.~Negative values for the differences indicate improvement. Missing values of SwoTS with non-missing values at assessments before and after were calculated using linear interpolation." (NCT01048866)
Timeframe: Baseline (pre-dose), hourly readings to 2 hours post-dose
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -35.5 |
Placebo Lozenge | -16.9 |
"SwoTS measures how swollen a participant's throat felt using a 100-mm visual analog scale completed by participants. Participants were instructed to swallow and Place a line on the scale that best characterizes how swollen your throat feels now. A mark at 0-mm indicated not swollen and 100-mm indicated very swollen.~The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -100320 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31680 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS. Negative values for differences indicate improvement." (NCT01048866)
Timeframe: Baseline (pre-dose), hourly readings to 24 hours post-dose
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -542.4 |
Placebo Lozenge | -377.4 |
"Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat? Responses were poor, fair, good, very good or excellent." (NCT01048866)
Timeframe: 24 hours
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Poor | Fair | Good | Very Good | Excellent | |
Flurbiprofen 8.75 mg Lozenge | 25.0 | 27.0 | 26.0 | 14.0 | 8.0 |
Placebo Lozenge | 25.3 | 29.5 | 24.2 | 12.6 | 8.4 |
"Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of study by answering the following question: Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat? Responses were poor, fair, good, very good or excellent." (NCT01048866)
Timeframe: Day 7 (end of study)
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Poor | Fair | Good | Very Good | Excellent | |
Flurbiprofen 8.75 mg Lozenge | 19.8 | 22.9 | 24.0 | 26.0 | 7.3 |
Placebo Lozenge | 25.0 | 26.1 | 20.7 | 22.8 | 5.4 |
After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied. (NCT01048866)
Timeframe: 24 hours
Intervention | percentage of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Extremely dissatisfied | Very dissatisfied | Dissatisfied | Somewhat satisfied | Satisfied | Very satisified | Extremely satisfied | |
Flurbiprofen 8.75 mg Lozenge | 4.0 | 4.0 | 10.9 | 27.7 | 23.8 | 24.8 | 5.0 |
Placebo Lozenge | 5.2 | 9.4 | 14.6 | 32.3 | 26.0 | 7.3 | 5.2 |
Participants were allowed a dose of rescue medication (acetaminophen 650mg), as needed, post-treatment dosing during the study. (NCT01048866)
Timeframe: Days 1-7
Intervention | percentage of participants (Number) | |
---|---|---|
Yes | No | |
Flurbiprofen 8.75 mg Lozenge | 13.9 | 86.1 |
Placebo Lozenge | 25.8 | 74.2 |
"Participants graded the relief of his/her sore throat at 2 hours after taking a lozenge for all lozenges taken after the initial 24-hours post-baseline using the Sore Throat Relief Rating Scale (STRRS), which is a 6-category relief scale.~The patient was instructed to swallow and:~Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now. Responses following each lozenge were no relief, slight, mild, moderate, considerable, and complete relief. Results summarize responses 2 hours after taking each lozenge." (NCT01048866)
Timeframe: Days 2-7
Intervention | percentage of doses (Number) | |||||
---|---|---|---|---|---|---|
No relief | Slight relief | Mild relief | Moderate relief | Considerable relief | Complete relief | |
Flurbiprofen 8.75 mg Lozenge | 9.7 | 21.7 | 25.2 | 16.5 | 18.9 | 8.0 |
Placebo Lozenge | 23.0 | 24.8 | 19.0 | 13.7 | 14.7 | 4.9 |
"Participants graded the relief of his/her sore throat at 2 hours post initial dose using the Sore Throat Relief Rating Scale (STRRS), which is a 6-category relief scale.~The patient was instructed to swallow and asked:~Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now. Responses were no relief, slight, mild, moderate, considerable, and complete relief." (NCT01048866)
Timeframe: 2 hours
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
No relief | Slight relief | Mild relief | Moderate relief | Considerable relief | |
Flurbiprofen 8.75 mg Lozenge | 9.9 | 28.7 | 27.7 | 17.8 | 15.8 |
Placebo Lozenge | 38.1 | 22.7 | 17.5 | 18.6 | 3.1 |
Participants were allowed a dose of rescue medication (acetaminophen 650mg), as needed, post-treatment during the study. Time from initial dose to first rescue medication is summarized by time categories. (NCT01048866)
Timeframe: Days 1-7
Intervention | percentage of participants (Number) | |||||
---|---|---|---|---|---|---|
2 - <4 hours | 4 - <6 hours | 6 - <24 hours | 24 - <72 hours | 72 - 168 hours | Did not rescue | |
Flurbiprofen 8.75 mg Lozenge | 2.0 | 2.0 | 5.9 | 3.0 | 1.0 | 86.1 |
Placebo Lozenge | 6.2 | 2.1 | 13.4 | 3.1 | 1.0 | 74.2 |
"Tonsillo-Pharyngitis Assessment, or TPA, is an index of seven clinical features of the pain-producing condition itself, pharyngeal inflammation. The clinical features concern temperature, oropharyngeal color, size of tonsils, number of enanthems, largest size of cervical lymph node, number of lymph nodes, and maximum tenderness of lymph nodes. Each variable was rated on a scale of 0-3, with 0 representing the normal value, and 3 representing severe inflammation. The seven values are added together to create the TPA, ranging from 0-21.~Negative change values represent improvement of symptoms." (NCT01049334)
Timeframe: Baseline (pre-dose), 24 hours post-dose
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -1.2 |
Placebo Lozenge | -2.0 |
"As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial.~An alternative definition of STPIS time to onset of relief was the time from initial dose to the time the participant reaching DIL for at least 30 minutes. Data were censored if DIL was not achieved by 120 minutes following initial dose. Definite improvement must also occur prior to re-dosing or using rescue medication." (NCT01049334)
Timeframe: 2 hours
Intervention | minutes (Median) |
---|---|
Flurbiprofen 8.75 mg Lozenge | NA |
Placebo Lozenge | NA |
"As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial.~The time of first achieving DIL for 30 minutes within 6 hours (or until rescue or re-dosing) post-dosing will be determined. And the time falling below DIL within 6 hours will be determined. Duration is then defined as the time from first DIL until falling below DIL. Duration was set to zero if the STPIS score does not reach the DIL for at least 30 minutes for STPIS during the 6 hours." (NCT01049334)
Timeframe: 6 hours
Intervention | minutes (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | 75.2 |
Placebo Lozenge | 29.4 |
"STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dosing. The full range was -9405 (complete pain relief within 2 minutes of dosing that lasts 2 hours) to 2395 (maximum pain within 2 minutes lasting 2 hours) using the mean baseline STPIS.~If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose." (NCT01049334)
Timeframe: baseline (pre-dose), 2 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2)
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -43.4 |
Placebo Lozenge | -23.5 |
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time-weighted pain intensity differences from baseline until 24 hours. The full range was -114609 (complete pain relief within 2 minutes of dosing that lasts 24 hours) to 29191 (maximum pain within 2 minutes lasting 24 hours) using the mean baseline STPIS. Participants with a last recorded time point <21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose. (NCT01049334)
Timeframe: baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)
Intervention | units on a scale (Least Squares Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -473.7 |
Placebo Lozenge | -322.3 |
"STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -116196 (no pain at any post-dose time (0) - average baseline) to 27804 (maximum possible pain (100) - average baseline).~Participants with their last recorded time point <21 hours were considered Not Evaluable. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation." (NCT01049334)
Timeframe: baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -451.4 |
Placebo Lozenge | -283.4 |
"Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and 2 hours post dose.~Participants were instructed to swallow and Place a line on the scale that best characterizes how difficult it is to swallow now. A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9192 (no difficulty swallowing within 10 minutes of dosing that lasts 2 hours) to 2808 (maximum difficulty swallowing within 10 minutes lasting 2 hours) using the baseline DSS value.~Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation." (NCT01049334)
Timeframe: baseline (pre-dose), 2 hours post-dose (every 10 minutes until hour 2)
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -39.1 |
Placebo Lozenge | -16.6 |
"Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and until 24 hours post dose.~Participants were instructed to swallow and Place a line on the scale that best characterizes how difficult it is to swallow now. A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -110304 (no difficulty swallowing within 10 minutes of dosing that lasts 24 hours) to 33696 (maximum difficulty swallowing within 10 minutes lasting 24 hours) using the baseline DSS value.~Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation." (NCT01049334)
Timeframe: baseline (pre-dose), 24 hours post-dose (every 10 minutes until hour 2, every 30 minutes until hour 6, hourly from 7-24 hours)
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -460.8 |
Placebo Lozenge | -274.3 |
"The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours.~The patient was instructed to swallow and Place a line on the scale that best characterizes how swollen your throat feels now. A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9336 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2664 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS." (NCT01049334)
Timeframe: baseline (pre-dose), 2 hours post-dose (at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours)
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -39.9 |
Placebo Lozenge | -20.1 |
"The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and specified timeframes until 24 hours.~The patient was instructed to swallow and Place a line on the scale that best characterizes how swollen your throat feels now. A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -112032 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31968 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS." (NCT01049334)
Timeframe: baseline (pre-dose), 24 hours post-dose (1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, 2 hours, 2½ hours, 3 hours, 3½ hours, 4 hours, 4½ hours, 5 hours, 5½ hours, and 6 hours after the first dose, hourly from 7-24 hours)
Intervention | units on a scale (Mean) |
---|---|
Flurbiprofen 8.75 mg Lozenge | -472.2 |
Placebo Lozenge | -355.2 |
"Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat? Responses were poor, fair, good, very good or excellent." (NCT01049334)
Timeframe: 24 hours
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Poor | Fair | Good | Very Good | Excellent | |
Flurbiprofen 8.75 mg Lozenge | 15.8 | 34.7 | 19.8 | 13.9 | 15.8 |
Placebo Lozenge | 38.0 | 28.0 | 18.0 | 13.0 | 3.0 |
"Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of the study by answering the following question: Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat? Responses were poor, fair, good, very good or excellent." (NCT01049334)
Timeframe: Day 7
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
Poor | Fair | Good | Very Good | Excellent | |
Flurbiprofen 8.75 mg Lozenge | 11.8 | 28.0 | 30.1 | 17.2 | 12.9 |
Placebo Lozenge | 31.6 | 34.7 | 14.7 | 14.7 | 4.2 |
After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied. (NCT01049334)
Timeframe: 24 hours
Intervention | percentage of participants (Number) | ||||||
---|---|---|---|---|---|---|---|
Extremely dissatisfied | Very dissatisfied | Dissatisfied | Somewhat satisfied | Satisfied | Very satisfied | Extremely satisfied | |
Flurbiprofen 8.75 mg Lozenge | 5.0 | 6.9 | 11.9 | 29.7 | 20.8 | 23.8 | 2.0 |
Placebo Lozenge | 10.0 | 20.0 | 14.0 | 28.0 | 17.0 | 9.0 | 2.0 |
P.A.I.N is a four step scale in which physicians rate the severity of pharyngeal inflammation: No inflammation, mild, moderate and severe inflammation. (NCT01049334)
Timeframe: 24 hours post-dose
Intervention | participants (Number) | |||
---|---|---|---|---|
No inflammation | Mild inflammation | Moderate inflammation | Severe inflammation | |
Flurbiprofen 8.75 mg Lozenge | 0 | 48 | 42 | 11 |
Placebo Lozenge | 1 | 42 | 50 | 7 |
"Participants used a 6-category relief scale (no relief to complete relief) to grade the relief of his/her throat pain.~The patient was instructed to swallow and:~Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now." (NCT01049334)
Timeframe: 2 hours
Intervention | percentage of participants (Number) | |||||
---|---|---|---|---|---|---|
No relief | Slight relief | Mild relief | Moderate relief | Considerable relief | Complete relief | |
Flurbiprofen 8.75 mg Lozenge | 18.6 | 23.5 | 23.5 | 20.6 | 13.7 | 0 |
Placebo Lozenge | 45.1 | 24.5 | 11.8 | 13.7 | 4.9 | 0 |
"Data reported in summary form in Primary Outcome #1 are reported here at each post-dose timepoint until the comparison resulted in a P-value <=0.05 between the two treatment arms.~STPIS was used to measure sore throat pain intensity using a 100-mm visual analog scale completed by participants that measures pain on swallowing (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. The full range of the scale varies by timepoint due to the time weighting sum of SPID. The full scale at 40 minutes post dose was -3188 (complete pain relief within 2 minutes of dosing that lasts 40 minutes) to 812 (maximum pain within 2 minutes lasting 40 minutes) using the mean baseline STPIS.~If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (rec" (NCT01049334)
Timeframe: baseline (pre-dose), up to 23 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-23)
Intervention | units on a scale (Mean) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Minutes post dose: 2 | Minutes post dose: 4 | Minutes post dose: 6 | Minutes post dose: 8 | Minutes post dose: 10 | Minutes post dose: 12 | Minutes post dose: 14 | Minutes post dose: 16 | Minutes post dose: 18 | Minutes post dose: 20 | Minutes post dose: 22 | Minutes post dose: 24 | Minutes post dose: 26 | Minutes post dose: 28 | Minutes post dose: 30 | Minutes post dose: 32 | Minutes post dose: 34 | Minutes post dose: 36 | Minutes post dose: 38 | Minutes post dose: 40 | |
Flurbiprofen 8.75 mg Lozenge | -0.1 | -0.3 | -0.6 | -0.9 | -1.4 | -1.9 | -2.4 | -3.0 | -3.5 | -4.1 | -4.7 | -5.2 | -5.9 | -6.5 | -7.2 | -7.9 | -8.6 | -9.3 | -10.1 | -10.8 |
Placebo Lozenge | -0.2 | -0.4 | -0.8 | -1.2 | -1.6 | -2.1 | -2.5 | -2.9 | -3.3 | -3.7 | -4.1 | -4.5 | -4.9 | -5.3 | -5.8 | -6.2 | -6.6 | -7.1 | -7.5 | -7.9 |
1 review available for flurbiprofen and Sore Throat
Article | Year |
---|---|
Delayed hypersensitivity to flurbiprofen.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Eruptions; Female; Flurbiprofen; Humans; Hypers | 1997 |
19 trials available for flurbiprofen and Sore Throat
Article | Year |
---|---|
[Results of a clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pharyngitis; Pro | 2022 |
[Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pain Measurement | 2022 |
[Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pain Measurement | 2022 |
[Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pain Measurement | 2022 |
[Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pain Measurement | 2022 |
[Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pain Measurement | 2022 |
[Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pain Measurement | 2022 |
[Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pain Measurement | 2022 |
[Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pain Measurement | 2022 |
[Results of the clinical study of the combination of flurbiprofen and cetylpyridinium chloride in patients with sore throat].
Topics: Adult; Cetylpyridinium; Double-Blind Method; Flurbiprofen; Humans; Hyperemia; Pain; Pain Measurement | 2022 |
Meaningful relief with flurbiprofen 8.75 mg spray in patients with sore throat due to upper respiratory tract infection.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Flurbiprofen; Hu | 2018 |
Qualities of Sore Throat Index (QuaSTI): measuring descriptors of sore throat in a randomized, placebo-controlled trial.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; F | 2018 |
Oral flurbiprofen spray for postoperative sore throat and hoarseness: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aerosols; Anti-Inflammatory Agents, Non-Steroidal; Benzydamine; Double-Blind Meth | 2019 |
Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial.
Topics: Adolescent; Adult; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Australia; Deglutition Disor | 2013 |
Onset of action of a lozenge containing flurbiprofen 8.75 mg: a randomized, double-blind, placebo-controlled trial with a new method for measuring onset of analgesic activity.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Double-Blind Method; Drug Delivery Systems; Fem | 2014 |
Comparison of Siccoral® spray, Stomatovis ® gargle, and Strefen ® lozenges on postoperative sore throat.
Topics: Acetylcysteine; Adolescent; Adult; Aerosols; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fl | 2014 |
[Effects of dezocine on postoperative sore throat after maxillofacial procedures: a comparison with flurbiprofen axetil].
Topics: Adult; Bridged Bicyclo Compounds, Heterocyclic; Double-Blind Method; Flurbiprofen; Humans; Oral Surg | 2014 |
Utility of the sore throat pain model in a multiple-dose assessment of the acute analgesic flurbiprofen: a randomized controlled study.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Deglutition; Double-Blind Method; Drug Administ | 2014 |
Utility of the sore throat pain model in a multiple-dose assessment of the acute analgesic flurbiprofen: a randomized controlled study.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Deglutition; Double-Blind Method; Drug Administ | 2014 |
Utility of the sore throat pain model in a multiple-dose assessment of the acute analgesic flurbiprofen: a randomized controlled study.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Deglutition; Double-Blind Method; Drug Administ | 2014 |
Utility of the sore throat pain model in a multiple-dose assessment of the acute analgesic flurbiprofen: a randomized controlled study.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Deglutition; Double-Blind Method; Drug Administ | 2014 |
Randomised, double-blind, placebo-controlled studies on flurbiprofen 8.75 mg lozenges in patients with/without group A or C streptococcal throat infection, with an assessment of clinicians' prediction of 'strep throat'.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Flurbiprofen; Humans; Male; Mi | 2015 |
Randomised, double-blind, placebo-controlled studies on flurbiprofen 8.75 mg lozenges in patients with/without group A or C streptococcal throat infection, with an assessment of clinicians' prediction of 'strep throat'.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Flurbiprofen; Humans; Male; Mi | 2015 |
Randomised, double-blind, placebo-controlled studies on flurbiprofen 8.75 mg lozenges in patients with/without group A or C streptococcal throat infection, with an assessment of clinicians' prediction of 'strep throat'.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Flurbiprofen; Humans; Male; Mi | 2015 |
Randomised, double-blind, placebo-controlled studies on flurbiprofen 8.75 mg lozenges in patients with/without group A or C streptococcal throat infection, with an assessment of clinicians' prediction of 'strep throat'.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Flurbiprofen; Humans; Male; Mi | 2015 |
Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: A randomised controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Australia; Double-Blind Method; Fe | 2016 |
Efficacy of flurbiprofen 8.75 mg lozenge in patients with a swollen and inflamed sore throat.
Topics: Adolescent; Adult; Analgesics; Female; Flurbiprofen; Humans; Male; Pharyngitis; Young Adult | 2016 |
Flurbiprofen 8.75 mg lozenges for treating sore throat symptoms: a randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; Flurbiprofen; Humans; Male; Pa | 2016 |
[Results of an open prospective controlled randomized comparative trial of flurbiprofen and paracetamol efficacy and tolerance in patients with throat pain].
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Female; Flurbiprofen; Humans; Male | 2005 |
Relief of sore throat with the anti-inflammatory throat lozenge flurbiprofen 8.75 mg: a randomised, double-blind, placebo-controlled study of efficacy and safety.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Flurb | 2000 |
Multidose flurbiprofen 8.75 mg lozenges in the treatment of sore throat: a randomised, double-blind, placebo-controlled study in UK general practice centres.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Flurbiprofen; Humans; M | 2002 |
Demonstration of dose response of flurbiprofen lozenges with the sore throat pain model.
Topics: Administration, Oral; Adolescent; Adult; Analgesics; Analysis of Variance; Chi-Square Distribution; | 2002 |
Clinical evaluation of flurbiprofen alone and plus ampicillin in chronic pharyngitis in acute phase.
Topics: Acute Disease; Adult; Aged; Ampicillin; Body Temperature; Clinical Trials as Topic; Drug Therapy, Co | 1986 |
4 other studies available for flurbiprofen and Sore Throat
Article | Year |
---|---|
Predicting local drug availability of locally acting lozenges: From method design to a linear level A IVIVC.
Topics: Administration, Oral; Adult; Analgesics; Drug Liberation; Flurbiprofen; Healthy Volunteers; Humans; | 2018 |
Fatal hypersensitivity reaction to an oral spray of flurbiprofen: a case report.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug | 2013 |
Topical treatments for postoperative sore throat.
Topics: Acetylcysteine; Female; Flurbiprofen; Humans; Male; Mouthwashes; Pharyngitis; Postoperative Complica | 2015 |
Flurbiprofen: new indication. Lozenges: NSAIDs are not to be taken like sweets!
Topics: Acetaminophen; Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Can | 2007 |